In clinical trials [201], PC-SPES reduced serum levels of prostate-specific androgen (PSA),a marker of prostatic cancer, in patients with both the androgen-dependent and androgen-independent type of this malignancy, although some patients of the both types subsequently experienced disease progression. The gene discussed is PROS1; the disease is prostate cancer.